|
|
|
Sunday, March 18, 2012 — 8:30 a.m. — Convention Centre 205-207
|
- Atherosclerosis: New Insights on an Old and Future Scourge
|
|
Moderators:
|
John P. Veinot, The Ottawa Hospital, Ottawa, ON, Canada and Richard N. Mitchell, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
|
Click the button above to add this event to your Itinerary Planner...
| 8:30 |
Pathobiology of Atherosclerosis - Michael A. Gimbrone, Brigham and Women's Hospital, Harvard Medical School, Boston, MA |
| 9:00 |
Imaging Atherosclerosis in Vivo: the Quest for the Vulnerable Plaque - Brett Bouma, Massachusetts General Hospital, Massachusetts Institute of Technology, Boston, MA |
| 9:30 | Break |
| 10:00 |
Cardiovascular Risk and Atherosclerosis Prevention - Jiri Frohlich, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada |
| 10:30 |
Atherosclerosis Intervention: Stents and Restenosis - Robert Boone, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada |
| 11:00 |
New Insights into the Puzzling Pathogenesis of Calcific Aortic Stenosis - Avrum Gotlieb, University of Toronto, Toronto, ON, Canada |
Atherosclerosis—and its sequelae in the coronary and cerebral circulations—remains the major cause of morbidity and mortality in industrialized countries; this, in the setting of remarkable progress in identifying risk factors and genetic associations, as well as developing diagnostic modalities and therapeutic interventions. Although there is an increasingly sophisticated view of the pathobiology, we still cannot prevent atherosclerosis, nor can we prognosticate or inhibit acute and potentially catastrophic plaque rupture. A more recent wrinkle is that the mechanisms that lead to vascular pathology in atherosclerosis may also underly calcific aortic valvular disease.
The Education Committee of the SCVP has therefore selected this topic because clinicians and pathologists alike encounter atherosclerosis and its manifestations on a daily basis. And although the pathogenesis and pathologic manifestations may seem to be well-established, there are several new developments—at all levels from endothelial cell biology to imaging and intervention—that merit a re-evaluation and update. To conclude, the session will be also be capped by the recipient of the SCVP Distinguished Achievement Award speaking on how calcific aortic valvular disease may be part of the larger atherosclerosis picture.
The objectives of the session are to present organizing principles for understanding the pathogenesis of atherosclerosis, and to highlight new developments and innovations in risk stratification, imaging (particularly identifying vulnerable plaque), and subsequent treatment.
|
|
|
|
